DarioHealth Corp. is a vertically integrated health intelligence platform that provides digital solutions for chronic care management and behavioral health. The company operates a whole-person health model that combines FDA-cleared connected hardware devices, artificial intelligence built on proprietary physiological data, and a behavior change and coaching layer. Its integrated suite of solutions addresses physical health conditions such as diabetes, hypertension, obesity, and musculoskeletal issues, as well as mental health needs including stress, anxiety, and depression. DarioHealth serves four primary market segments: the direct-to-consumer (D2C) market, medium-to-large employers, national and regional health plans, and global pharmaceutical companies. In the employer segment, the company provides chronic condition management and patient engagement solutions to employees, often through value-based pricing frameworks. For health plans, it offers specialized behavioral health and chronic care solutions, particularly for Medicare and Medicaid members. In the pharmaceutical sector, DarioHealth delivers patient education, medication adherence support, and patient journey data analytics. The company generates revenue through risk-based agreements with performance guarantees and utilizes a multi-condition platform to reduce duplicative spending for customers. DarioHealth’s platform is supported by partnerships with employers, health plans, and pharmaceutical companies to deliver integrated self-care and virtual clinical care.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Health Information Services Homepage dariohealth.com
Sector Healthcare IR page dariohealth.investorroom.com/InvestorsAlerts
Tags
digital health, chronic care management, behavioral health, cardiometabolic conditions, musculoskeletal conditions, ai-driven health, direct-to-consumer, employer benefits, health plan services, pharmaceutical services, value-based care, patient engagement, Twill, Twill Inc.
Press page —

Metrics

Valuation  
Market cap $ 74.124M
Market cap (USD) $ 74.124M
P/E —
PEG —
P/BV 1.04
P/S 3.48
P/OCF -3.15
P/FCF -3.13
Dividend yield —
Turnover / mcap —
Returns  
ROE -59.6%
ROI -42.3%
ROIC -27.9%
Profit margin -186.6%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity 43.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -46.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 22.359M 27.04M 20.352M 27.656M 20.513M 7.576M 7.559M 7.394M 5.17M 2.803M 823K 51K — —
Net profit -41.714M -42.747M -59.427M -62.193M -76.761M -29.445M -17.736M -17.803M -15.743M -10.887M -7.142M -12.877M -13.932M -5.687M
Free cash flow -26.083M -38.7M -30.963M -48.287M -50.67M -17.854M -15.823M -11.541M -10.814M -9.187M -6.387M -9.144M -9M -3.517M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 11.38 0.79 1.72 4.28 12.97 14.29 6.56 0.79 1.63 3.25 — — — —
Price performance 12m 13.48 -0.54 -0.6 -0.67 -0.09 1.18 7.28 -0.51 -0.5 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 0.00 — — — — — — — — —
↳ YoY growth -100.0%
Borrowings, current (USD) — — — — — 0.00 8.82M 3.95M 5.45M —
Borrowings, non-current (USD) — — — — — 0.00 18.1M 24.6M 23.5M 30.7M
Lease liabilities (USD) — — 0.00 772,000 532,000 287,000 1.12M 996,000 1.27M 1M
Cash and deposits (USD) 1.09M 3.72M 11M 20.4M 28.6M 35.8M 49.4M 36.8M 27.8M 21.8M
Intangible assets (USD) — — — — — 12.5M 9.92M 5.4M 18.8M 15.9M
Right-of-use assets (USD) — — 0.00 765,000 498,000 287,000 1.21M 967,000 1.07M 717,000
Net debt (borrowings + leases - cash) (USD) — — — — — -35.5M -21.3M -7.26M 2.43M 9.95M
Cash flow detail
Operating cash flow (USD) -8.38M -10.6M -11.5M -15.7M -17.7M -50.4M -47.8M -30.4M -38.6M -25.9M
Purchases of property, plant and equipment (USD) -808,000 -195,000 -71,000 -98,000 -118,000 -261,000 -442,000 -584,000 -138,000 -142,000
Purchases of intangible assets (USD) — — — — — — -131,000 — — —
Change in inventories (cash effect) (USD) -287,000 -295,000 -193,000 -37,000 -879,000 -2.23M -1.73M 2.89M 308,000 437,000
Share buybacks (cash effect) (USD) — — — — — — -134,000 — — —
Interest paid (cash effect) (USD) — — — — — — -1.88M -4.03M -3.93M -3.49M
Income taxes paid (cash effect) (USD) — — — — — — — — — -288,000
Share-based compensation (USD) 1.04M 3.82M 3.76M 2.32M 11.1M 25M 17M 19.7M 46,000 9.37M
Free cash flow (OCF - PPE - intangibles) (USD) -9.19M -10.8M -11.5M -15.8M -17.9M -50.7M -48.4M -31M -38.7M -26.1M
Income detail
Research and development expense (USD) 2.15M 3.3M 3.68M 3.69M 4.43M 17.2M 19.6M 20.2M 24.2M 13.8M
↳ 5y CAGR +17.0% -5.6% -1.3% +11.6% +51.5% +42.9% +40.7% +45.6% +25.5%
Total comprehensive income (USD) — — — — — -78.8M -63.8M -63.5M -41M -61.7M
Comprehensive income to owners (USD) — — — — — -78.8M -63.8M -63.5M -41M -61.7M
Provision for credit losses (USD) — — — — — — — 140,000 268,000 46,000
Reported Mar 22, 2017 Mar 19, 2018 May 13, 2019 Mar 17, 2020 Mar 9, 2021 Mar 9, 2023 Mar 9, 2023 May 15, 2024 Mar 10, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Mr. Palumbo to join Dario's third quarter 2026 earnings call to share the Board's view on the convergence of consumer and payer-led healthcare and chronic care management

NEW YORK, Nov. 4, 2026 /PRNewswire / -- DarioHealth Corp . (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that its Board of Directors (the "Board") has appointed John R. Palumbo as Chairman of the Board, effective November 3, 2026. Mr. Palumbo, who joined the Board in April 2026, succeeds Yoav Shaked, who has served as Chairman since 2018 and will continue to serve as a director.

DarioHealth Corp. Logo

The appointment comes as two historically separate healthcare markets converge. Consumers increasingly choose their own entry point into healthcare, through AI tools, home testing and direct access to branded men's and women's health therapies, while payers continue to fund the management of underlying chronic conditions, which account for roughly 90% of U.S. health spending. Payers are redesigning plan structures, and the Centers for Medicare and Medicaid Services ("CMS"), through its ACCESS Model launched in July 2026, now pays for outcomes in hypertension, diabetes, musculoskeletal conditions and depression – conditions that align with Dario's existing chronic care management offerings.

"For a decade, the industry treated consumer health and chronic care as two different businesses. They are becoming one, and Dario has spent that decade building the platform that sits where they meet," stated Dario's Chief Executive Officer, Erez Raphael. "John has spent his career inside the payer, provider and health services organizations that are shaping where this market is going, and he has worked hand-in-hand with our team since April. Having him lead our Board as we seek to capture this opportunity is a clear statement of our ambition."

"The consumer picks the door. The payer pays for the chronic condition behind it. I believe the value moves to whomever owns the path between the two and provides a bridge for the patient," said Mr. Palumbo. "Working alongside Erez and the team over the past six months, I have seen what the market may not yet fully appreciate: a strong team, a mission-driven culture focused on members and outcomes, and a platform built for exactly that path, with consumer engagement and payer-grade evidence integrated within a single platform. As Chairman, my focus is to make sure the Company captures the full strategic value of that position."

"It has been a privilege to chair Dario since 2018," said Mr. Shaked. "John is the right leader for the Board's next chapter, and I look forward to continuing to support the Company as a director."

Dario believes this convergence will shift chronic care management from single-condition apps to an AI-led, clinician-backed and reimbursable system, with one member record reachable from either the consumer door or the payer door. Dario has spent more than a decade building that system:

  • One platform, combining DarioIQ intelligence with Dario Care clinical services, with one clinical engine and one evidence base across conditions. More than 80% of Dario's contracted and late-stage annual recurring revenue ("ARR") is multi-condition.
  • A proprietary stack, including FDA-cleared connected devices in members' homes and more than 13 billion proprietary data points.
  • Experience on both sides of the market: consumer roots; more than 100 scientific studies; more than 180 signed enterprise accounts, including serving more than a dozen health plans.
  • Published clinical and economic evidence, including $5,077 in annual savings per user and 23.5% fewer inpatient discharges among members with type 2 diabetes, and an independent Aon review of 17 studies supporting a 2.5% to 7.2% in-year reduction in total healthcare costs.
  • A partner-led growth model, with approximately 75% of new accounts coming through channel partners.

Mr. Palumbo will join Dario's third quarter 2026 earnings conference call  on November 12, 2026, to share the Board's perspective on these market shifts and the Company's strategic priorities.

Mr. Palumbo brings more than 40 years of healthcare operating experience across early-stage ventures and Fortune 100 enterprises. His background includes senior leadership roles at AmerisourceBergen Corporation (now Cencora, Inc.), where he led the provider business unit and expanded consulting and technology capabilities into a multibillion-dollar platform serving health systems nationwide, as well as serving as Chief Operating Officer of Allscripts Healthcare Solutions, Inc. (now Veradigm, Inc.) and holding leadership positions at Shared Medical Systems Corporation (now Oracle). He has supported two companies through IPOs and led large-scale operational and commercial transformations.

He currently serves on the boards of PM Pediatrics Management Group, LLC, Lucid Diagnostics Inc., ivWatch, LLC and Qless, Inc., and chairs the advisory board of Brado Cuneo Nollau, LLC, an AI-driven engagement platform serving health systems.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expectations regarding the convergence of consumer-directed and payer-funded healthcare; anticipated changes in healthcare delivery, reimbursement and chronic care management models, including the potential implications of the CMS ACCESS Model; the Company's ability to capitalize on these market developments and its positioning within the evolving healthcare market; the anticipated strategic benefits of Mr. Palumbo's appointment as Chairman of the Board and his expected contributions to the Company's strategic direction, commercial development and growth initiatives; the Company's expectations regarding the continued development, integration, adoption and scalability of its AI-powered chronic care management platform; the potential clinical, operational and economic benefits of the Company's solutions, including potential improvements in patient outcomes and reductions in healthcare costs; the Company's ability to expand its relationships with health plans, employers, health systems, government entities and channel partners; and the Company's future business strategy, growth opportunities, market positioning and commercial performance. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
[email protected]

+1-201-785-6310

Rob Halpern
SVP Marketing
[email protected]   

SOURCE DarioHealth Corp.

Get it on App Store Get it on Google Play Secure Payment Secure SSL HSA/FSA FDA

Contact Us

Follow Us

Supported Devices

Dario Support Toll-Free: 833-914-3796

© 2026 DarioHealth Corp. View our Privacy Policy or Terms and Conditions

DarioHealth is a publicly traded company (Nasdaq: DRIO).

Supported Devices

iOS Application version – 4.3.1
Supported iOS phones (Audio Jack): iPhone 5, 5s, SE, 6, 6 Plus, 6s, 6s Plus

Supported iOS phones (LC): 7, 7 Plus, 8, 8 Plus, X, Xs, Xs Max, XR, 11, 11 Pro, 11 Pro Max, SE 2020
iOS Operating System: 10, 11, 12, 13

(*) Note: iPhone7, 7 Plus, 8, 8 Plus, X, Xs, Xs Max, Xr are supported with the product Dario LC Blood Glucose Monitoring System.

Android Application version – 4.5.0

Supported Android phones (Audio Jack):
LG G6, G7, G8.
Samsung Galaxy S6, S6 Edge, S7, S7 Edge, S8, S8+, S9, S9+, S10, S10+, S10e, S10 5G.
Galaxy Note 4, 5, 8, 9

Supported Android phones (USB-C):
LG G6, G7, G8.
Samsung Galaxy S8, S8+, S9, S9+, S10, S10+, S10e, S10 5G, S20, S20+, S20 Ultra.
Galaxy Note 8, 9, 10, 10+
Google Pixel 3, 3 XL, 4, 4 XL

Android Operating System: 6, 7, 8, 9

×

(opens in a new window)

On November 3, 2026, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, the Board appointed John R. Palumbo as Chairman of the Board, effective immediately, succeeding Yoav Shaked, who will continue to serve as a member of the Board.

Company to host conference call and webcast at 8:30 a.m. Eastern Time

NEW YORK, Nov. 2, 2026 /PRNewswire / -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, November 12th, 2026, before the market opens.

DarioHealth Corp. Logo

Erez Raphael, Chief Executive Officer, Lara Dodo, Chief Operations Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.

Conference Call Details

Date: Thursday, November 12th, 2026, 8:30 a.m. Eastern Time

Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

Call me™:  https://emportal.ink/4623c5K

Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.

Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1775359&tp_key=4596015d94

Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Thursday, November 26th, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1139413.

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected date of its earnings release. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact

Zoe Harrison
VP, Accounting and Corporate Development
[email protected]

DarioHealth Investor Relations Contact

Michael Lipari
SVP Corporate Development
[email protected]

+1-203-785-6310

SOURCE DarioHealth Corp.

Get it on App Store Get it on Google Play Secure Payment Secure SSL HSA/FSA FDA

Contact Us

Follow Us

Supported Devices

Dario Support Toll-Free: 833-914-3796

© 2026 DarioHealth Corp. View our Privacy Policy or Terms and Conditions

DarioHealth is a publicly traded company (Nasdaq: DRIO).

Supported Devices

iOS Application version – 4.3.1
Supported iOS phones (Audio Jack): iPhone 5, 5s, SE, 6, 6 Plus, 6s, 6s Plus

Supported iOS phones (LC): 7, 7 Plus, 8, 8 Plus, X, Xs, Xs Max, XR, 11, 11 Pro, 11 Pro Max, SE 2020
iOS Operating System: 10, 11, 12, 13

(*) Note: iPhone7, 7 Plus, 8, 8 Plus, X, Xs, Xs Max, Xr are supported with the product Dario LC Blood Glucose Monitoring System.

Android Application version – 4.5.0

Supported Android phones (Audio Jack):
LG G6, G7, G8.
Samsung Galaxy S6, S6 Edge, S7, S7 Edge, S8, S8+, S9, S9+, S10, S10+, S10e, S10 5G.
Galaxy Note 4, 5, 8, 9

Supported Android phones (USB-C):
LG G6, G7, G8.
Samsung Galaxy S8, S8+, S9, S9+, S10, S10+, S10e, S10 5G, S20, S20+, S20 Ultra.
Galaxy Note 8, 9, 10, 10+
Google Pixel 3, 3 XL, 4, 4 XL

Android Operating System: 6, 7, 8, 9

×

(opens in a new window)

Prompts

DarioHealth Corp. (ticker DRIO), listed in United States.

Company History

Date Change Detail
Jul 28, 2016 Renamed LABSTYLE INNOVATIONS CORP. → DARIOHEALTH CORP.

ETFs Holding DarioHealth Corp.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 747 $ 1,232.55 Nov 12, 2026
DCOR 0.00% 1,200 $ 1,980.00 Nov 12, 2026